These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 26548839)

  • 1. Using an in vitro xenoantibody-mediated complement-dependent cytotoxicity model to evaluate the complement inhibitory activity of the peptidic C3 inhibitor Cp40.
    Wang J; Wang L; Xiang Y; Ricklin D; Lambris JD; Chen G
    Clin Immunol; 2016 Jan; 162():37-44. PubMed ID: 26548839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic C3 inhibitor Cp40 abrogates complement activation induced by modern hemodialysis filters.
    Reis ES; DeAngelis RA; Chen H; Resuello RR; Ricklin D; Lambris JD
    Immunobiology; 2015 Apr; 220(4):476-82. PubMed ID: 25468722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Compstatin analog Cp40 inhibits complement dysregulation in vitro in C3 glomerulopathy.
    Zhang Y; Shao D; Ricklin D; Hilkin BM; Nester CM; Lambris JD; Smith RJ
    Immunobiology; 2015 Aug; 220(8):993-8. PubMed ID: 25982307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria.
    Risitano AM; Ricklin D; Huang Y; Reis ES; Chen H; Ricci P; Lin Z; Pascariello C; Raia M; Sica M; Del Vecchio L; Pane F; Lupu F; Notaro R; Resuello RR; DeAngelis RA; Lambris JD
    Blood; 2014 Mar; 123(13):2094-101. PubMed ID: 24497537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complement C3 inhibitor Cp40 attenuates xenoreactions in pig hearts perfused with human blood.
    Abicht JM; Kourtzelis I; Reichart B; Koutsogiannaki S; Primikyri A; Lambris JD; Chavakis T; Holdt L; Kind A; Guethoff S; Mayr T
    Xenotransplantation; 2017 Jan; 24(1):. PubMed ID: 27677785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolonged intraocular residence and retinal tissue distribution of a fourth-generation compstatin-based C3 inhibitor in non-human primates.
    Hughes S; Gumas J; Lee R; Rumano M; Berger N; Gautam AK; Sfyroera G; Chan AL; Gnanaguru G; Connor KM; Kim BJ; Dunaief JL; Ricklin D; Hajishengallis G; Yancopoulou D; Reis ES; Mastellos DC; Lambris JD
    Clin Immunol; 2020 May; 214():108391. PubMed ID: 32229292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complement-Dependent Mechanisms and Interventions in Periodontal Disease.
    Hajishengallis G; Kajikawa T; Hajishengallis E; Maekawa T; Reis ES; Mastellos DC; Yancopoulou D; Hasturk H; Lambris JD
    Front Immunol; 2019; 10():406. PubMed ID: 30915073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Over-expression of heme oxygenase-1 does not protect porcine endothelial cells from human xenoantibodies and complement-mediated lysis.
    Zhang C; Wang L; Zhong S; Wang XX; Xiang Y; Chen S; Chen G
    J Huazhong Univ Sci Technolog Med Sci; 2013 Feb; 33(1):102-106. PubMed ID: 23392716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety profile after prolonged C3 inhibition.
    Reis ES; Berger N; Wang X; Koutsogiannaki S; Doot RK; Gumas JT; Foukas PG; Resuello RRG; Tuplano JV; Kukis D; Tarantal AF; Young AJ; Kajikawa T; Soulika AM; Mastellos DC; Yancopoulou D; Biglarnia AR; Huber-Lang M; Hajishengallis G; Nilsson B; Lambris JD
    Clin Immunol; 2018 Dec; 197():96-106. PubMed ID: 30217791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TNF-α promotes human antibody-mediated complement-dependent cytotoxicity of porcine endothelial cells through downregulating P38-mediated Occludin expression.
    Gao H; Cao M; Chen P; Cooper DKC; Zhao Y; Wei L; Xu J; Cai Z; Zeng C; Luan S; Mou L
    Cell Commun Signal; 2019 Jul; 17(1):75. PubMed ID: 31307477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention.
    Mastellos DC; Yancopoulou D; Kokkinos P; Huber-Lang M; Hajishengallis G; Biglarnia AR; Lupu F; Nilsson B; Risitano AM; Ricklin D; Lambris JD
    Eur J Clin Invest; 2015 Apr; 45(4):423-40. PubMed ID: 25678219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RNA interference of GGTA1 physiological and immune functions in immortalized porcine aortic endothelial cells.
    Han W; Zhou J; Li X; Wang J; Li J; Zhang Z; Yang Z; Wang D; Tao K; Dou K
    J Surg Res; 2013 Nov; 185(1):410-8. PubMed ID: 23809180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complement inhibition in a xenogeneic model of interactions between human whole blood and porcine endothelium.
    Kourtzelis I; Ferreira A; Mitroulis I; Ricklin D; Bornstein SR; Waskow C; Lambris JD; Chavakis T
    Horm Metab Res; 2015 Jan; 47(1):36-42. PubMed ID: 25350518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Analogs of the Complement C3 Inhibitor Compstatin with Increased Solubility and Improved Pharmacokinetic Profile.
    Berger N; Alayi TD; Resuello RRG; Tuplano JV; Reis ES; Lambris JD
    J Med Chem; 2018 Jul; 61(14):6153-6162. PubMed ID: 29920096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complement inhibition in pre-clinical models of periodontitis and prospects for clinical application.
    Hajishengallis G; Hajishengallis E; Kajikawa T; Wang B; Yancopoulou D; Ricklin D; Lambris JD
    Semin Immunol; 2016 Jun; 28(3):285-91. PubMed ID: 27021500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clonidine inhibits anti-non-Gal IgM xenoantibody elicited in multiple pig-to-primate models.
    Stewart JM; Tarantal AF; Hawthorne WJ; Salvaris EJ; O'Connell PJ; Nottle MB; d'Apice AJ; Cowan PJ; Kearns-Jonker M
    Xenotransplantation; 2015; 22(6):413-26. PubMed ID: 26490547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complement therapeutics in inflammatory diseases: promising drug candidates for C3-targeted intervention.
    Mastellos DC; Ricklin D; Hajishengallis E; Hajishengallis G; Lambris JD
    Mol Oral Microbiol; 2016 Feb; 31(1):3-17. PubMed ID: 26332138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dextran sulfate acts as an endothelial cell protectant and inhibits human complement and natural killer cell-mediated cytotoxicity against porcine cells.
    Laumonier T; Walpen AJ; Maurus CF; Mohacsi PJ; Matozan KM; Korchagina EY; Bovin NV; Vanhove B; Seebach JD; Rieben R
    Transplantation; 2003 Sep; 76(5):838-43. PubMed ID: 14501864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective Effects of the Complement Inhibitor Compstatin CP40 in Hemorrhagic Shock.
    van Griensven M; Ricklin D; Denk S; Halbgebauer R; Braun CK; Schultze A; Hönes F; Koutsogiannaki S; Primikyri A; Reis E; Messerer D; Hafner S; Radermacher P; Biglarnia AR; Resuello RRG; Tuplano JV; Mayer B; Nilsson K; Nilsson B; Lambris JD; Huber-Lang M
    Shock; 2019 Jan; 51(1):78-87. PubMed ID: 29461464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Compstatin inhibits complement activation by binding to the beta-chain of complement factor 3.
    Soulika AM; Holland MC; Sfyroera G; Sahu A; Lambris JD
    Mol Immunol; 2006 May; 43(12):2023-9. PubMed ID: 16472861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.